Seoulin Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	10,452	8,949	14,602	8,999	14,973
Short-Term Investments	22,256	14,467	20,722	41,319	40,360
Trading Asset Securities	2,008	93.22	90.3	4,962	19,999
Cash & Short-Term Investments	34,716	23,510	35,414	55,280	75,332
Cash Growth	47.67%	-33.62%	-35.94%	-26.62%	279.32%
Accounts Receivable	8,121	7,323	12,986	6,652	10,137
Other Receivables	408.81	528.24	1,291	630.36	196.33
Receivables	8,529	7,851	14,294	7,282	10,333
Inventory	24,721	26,245	21,785	17,307	13,933
Prepaid Expenses	33.28	13.63	53.74	51.32	32.59
Other Current Assets	4,035	2,222	1,408	7,366	5,352
Total Current Assets	72,035	59,841	72,955	87,287	104,983
Property, Plant & Equipment	16,839	16,628	18,914	16,491	14,937
Long-Term Investments	24,928	19,460	17,512	25,555	7,515
Goodwill	-	373.89	526.49	526.49	526.49
Other Intangible Assets	359.98	395.06	425.08	266.64	230.54
Long-Term Deferred Tax Assets	2,098	2,222	2,259	1,269	2,766
Long-Term Deferred Charges	69.65	107.82	156.08	210.96	558.01
Other Long-Term Assets	2,469	2,496	1,335	3,840	5,051
Total Assets	118,798	101,525	114,100	135,486	136,566
Accounts Payable	7,543	5,009	11,428	8,603	10,888
Accrued Expenses	477.01	390.22	387.97	373.05	329.11
Short-Term Debt	11,422	3,450	6,120	17,469	15,259
Current Portion of Long-Term Debt	-	-	-	62.5	256.25
Current Portion of Leases	95.56	156.68	271.44	69.22	34.65
Current Income Taxes Payable	-	-	700.11	730.13	4,561
Other Current Liabilities	12,132	4,628	9,122	19,058	28,112
Total Current Liabilities	31,669	13,634	28,030	46,365	59,440
Long-Term Debt	-	-	98.6	98.47	154.85
Long-Term Leases	62.61	73.29	224.29	86.11	32.85
Pension & Post-Retirement Benefits	537.63	478.96	254.11	-	285.87
Other Long-Term Liabilities	476.95	465.66	253.48	151.59	150
Total Liabilities	32,746	14,652	28,861	46,701	60,064
Common Stock	4,550	4,450	4,350	4,250	4,150
Additional Paid-In Capital	18,921	18,519	18,519	18,519	18,490
Retained Earnings	69,090	69,170	67,177	68,475	58,805
Treasury Stock	-4,555	-4,496	-3,404	-3,261	-3,062
Comprehensive Income & Other	-3,795	-3,751	-3,581	-3,581	-3,523
Total Common Equity	84,211	83,893	83,063	84,403	74,861
Minority Interest	1,841	2,980	2,177	4,382	1,642
Shareholders' Equity	86,052	86,872	85,239	88,785	76,502
Total Liabilities & Equity	118,798	101,525	114,100	135,486	136,566
Total Debt	11,580	3,680	6,714	17,785	15,738
Net Cash (Debt)	23,137	19,830	28,700	37,495	59,594
Net Cash Growth	16.68%	-30.91%	-23.46%	-37.08%	211.92%
Net Cash Per Share	1738.46	2279.74	3201.94	3369.03	6625.03
Filing Date Shares Outstanding	7.95	8.63	8.76	8.77	8.77
Total Common Shares Outstanding	7.95	8.96	8.97	8.98	8.99
Working Capital	40,366	46,207	44,924	40,922	45,543
Book Value Per Share	10586.85	9363.40	9262.33	9398.97	8324.26
Tangible Book Value	83,851	83,124	82,111	83,610	74,104
Tangible Book Value Per Share	10541.60	9277.57	9156.22	9310.65	8240.08
Land	4,074	3,967	4,246	3,721	3,185
Buildings	11,204	11,263	12,539	11,192	10,642
Machinery	1,281	1,026	1,474	1,193	851.95
Construction In Progress	-	-	-	6	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.